Drugs

Postmarket Drug and Biologic Safety Evaluations Completed from October 2016 – December 2016

 
Product Name: Trade (active ingredient)
with Dosage form NDA/BLA Number ("NME" indicates New Molecular Entity)  Approval Date
Major Indications Summary of Findings from Evaluation Actions taken and Ongoing Surveillance Activities

Argatroban
injection in 5% dextrose, for intravenous infusion only


NDA 201743
 

May 9, 2011

  • For use as prophylaxis or for treating thrombosis in adult patients with heparin-induced thrombocytopenia (HIT)
  • For use as an anticoagulant in patients with or at risk for HIT undergoing percutaneous coronary intervention

No new safety issues were identified.

No regulatory actions required at this time.

Benlysta
(belimumab)
injection, for intravenous use only
 

BLA 125370 (NME)
 

March 9, 2011

For treating adult patients with active, autoantibody-positive, systemic lupus erythematosus who are receiving standard therapy

No new safety issues were identified.

No regulatory actions required at this time.

Bloxiverz
(neostigmine methylsulfate)
injection, for intravenous use
 

NDA 204078
 

May 31, 2013

For reversing the effects of non-depolarizing neuromuscular blocking agents after surgery

No new safety issues were identified.

No regulatory actions required at this time.

Ceftazidime for injection USP and dextrose
injection USP,
for intravenous use
 

NDA 050823
 

June 13, 2011

For treating the following infections caused by susceptible isolates of the designated microorganisms:

  • lower respiratory tract infections
  • skin and skin-structure infections
  • bacterial septicemia
  • bone and joint infections
  • gynecologic infections
  • central nervous system infections

A safety issue of status epilepticus was identified from postmarketing adverse event reports.

FDA continues to evaluate the safety issue of status epilepticus to determine if regulatory action is required.

Coartem
(artemether and lumefantrine)
tablets, for oral use
 

NDA 022268 (NME)
 

April 7, 2009

For treating acute, uncomplicated malaria infections due to Plasmodium falciparum in patients of 5 kg bodyweight and above

A safety issue of hemolytic anemia, possibly associated with post-artemisinin delayed hemolysis, was identified from postmarketing adverse event reports.

FDA is evaluating adverse event reports of hemolytic anemia to determine if regulatory action is required.

Dotarem
(gadoterate meglumine) injection, for intravenous use
 

NDA 204781 (NME)
 

March 20, 2013

For use with magnetic resonance imaging in brain (intracranial), spine and associated tissues in patients 2 years of age and older to detect and visualize areas with disruption of the blood brain barrier and/or abnormal vascularity

No new safety issues were identified.

No regulatory actions are required at this time.

Harvoni
(ledipasvir and sofosbuvir)
tablets, for oral use
 

NDA 205834 (NME)
 

October 10, 2014

For use with or without ribavirin for treating patients with chronic hepatitis C virus genotype 1, 4, 5, or 6 infection

No new safety issues were identified.

No regulatory actions required at this time.

Hysingla ER
(hydrocodone bitartrate)
extended-release tablets, for oral use
 

NDA 206627
 

November 20, 2014

For managing pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

No new safety issues were identified.

No regulatory actions required at this time.

Invokamet
(canagliflozin and metformin hydrochloride)
tablets, for oral use
 

NDA 204353
 

August 8, 2014

For use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both canagliflozin and metformin is appropriate

A safety issue of nephrolithiasis was identified from postmarketing adverse event reports.

FDA continues to evaluate adverse event reports of nephrolithiasis to determine if regulatory action is required.

Jardiance
(empagliflozin)
tablets, for oral use
 

NDA 204629 (NME)
 

August 1, 2014

For use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Two safety issues were identified from postmarketing adverse event reports:

  • Acute kidney injury
  • Pancreatitis

In December 2016, the “Warnings and Precautions,” “Adverse Reactions,” and “Patient Counseling” sections of the prescribing information and the patient package insert were updated to include information regarding acute kidney injury.
FDA has completed its review of pancreatitis and has determined that no regulatory action is needed at this time.

Kcentra
(prothrombin complex concentrate (human))
 

BLA 125421
 

April 29, 2013

For the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (e.g., warfarin) therapy in adult patients with acute major bleeding or need an urgent surgery/invasive procedure

Reports of product label confusion and wrong dose administration were identified.

UpdatedJune 30, 2017

FDA completed its review of reports of product label confusion and wrong dose administration. In February 2017, the product labeling and the “Dosage and Administration” section of the prescribing information were revised to clarify the supplied dose. No further regulatory action is required at this time.

Lymphoseek
(technetium Tc 99m tilmanocept)
injection, for subcutaneous, intradermal, subareolar, or peritumoral use
 

NDA 202207 (NME)
 

March 13, 2013

A radioactive diagnostic agent for use with or without scintigraphic imaging:

  • to locate lymph nodes draining a primary tumor site in patients with solid tumors as part of intraoperative management;
  • to guide sentinel lymph node biopsy in patients with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer or melanoma

No new safety issues were identified.

No regulatory actions required at this time.

Movantik
(naloxegol)
tablets, for oral use
 

NDA 204760 (NME)
 

September 16, 2014

For treating opioid-induced constipation in adult patients with chronic non-cancer pain

No new safety issues were identified.

No regulatory actions required at this time.

Namzaric
(memantine and donepezil hydrochlorides) extended-release capsules, for oral use
 

NDA 206439
 

December 23, 2014

For the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily

No new safety issues were identified.

No regulatory actions required at this time.

Paricalcitol
injection, for intravenous use
 

NDA 201657
 

October 21, 2014

An active vitamin D2 analog for preventing and treating secondary hyperparathyroidism associated with chronic kidney disease Stage 5

No new safety issues were identified.

No regulatory actions required at this time.

Rytary
(carbidopa and levodopa)
extended-release capsules, for oral use
 

NDA 203312
 

January 7, 2015

For treating Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication

No new safety issues were identified.

No regulatory actions required at this time.

Soolantra
(ivermectin)
cream, 1%, for topical use
 

NDA 206255
 

December 19, 2014

For treating inflammatory lesions of rosacea

Two safety issues were identified from postmarketing adverse event reports:

  • Contact dermatitis
  • Allergic contact dermatitis

FDA is evaluating adverse event reports of contact dermatitis and allergic contact dermatitis to determine if regulatory action is required.

Subsys
(fentanyl)
sublingual spray
 

NDA 202788
 

January 4, 2012

For managing breakthrough pain in adult opioid tolerant cancer patients

A safety issue of a burning sensation at the application site was identified from postmarketing adverse event reports.

FDA is evaluating adverse event reports of a burning sensation at the application site to determine if regulatory action is required.

Testosterone
gel, for topical use
 

NDA 203098
 

January 31, 2013

For replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone

No new safety issues were identified.

No regulatory actions required at this time.

Tobi Podhaler
(tobramycin)
inhalation powder, for oral inhalation use
 

NDA 201688
 

March 22, 2013

For managing cystic fibrosis patients with Pseudomonas aeruginosa

No new safety issues were identified.

No regulatory actions required at this time.

Trulicity
(dulaglutide)
injection, for subcutaneous use
 

BLA 125469 (NME)
 

September 18, 2014

For use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

A safety issue of device malfunction was identified from postmarketing adverse event reports.

FDA continues to evaluate reports of device malfunction to determine if regulatory action is required.

Xigduo XR (dapagliflozin and metformin hydrochloride
extended-release) tablets, for oral use
 

NDA 205649
 

October 29, 2014

For use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate

No new safety issues were identified.

No regulatory actions required at this time.

 

Page Last Updated: 10/06/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English